Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prednisolone with SPI-62 (Clofutriben) in Polymyalgia Rheumatica
NCT05436652Phase 2Completed
- Sponsor
- Sparrow Pharmaceuticals
- Start
- Jul 2022
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, single-blind trial of clofutriben in polymyalgia rheumatica (PMR) (2 arms), sponsored by Sparrow Pharmaceuticals. Primary endpoints: Erythrocyte sedimentation rate at Day 28, C-reactive protein at Day 28 and 1 more. Started Jul 2022; status: completed.
02
Drugs
clofutriben
03
Conditions
polymyalgia rheumatica (PMR)
Beyond the preview
Go deeper on NCT05436652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05436652.